Roche Culls Myostatin Candidate From Obesity Pipeline

Roche culls myostatin candidate from obesity pipeline

Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.

Roche Halts Development of Obesity Drug Candidate

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Roche cans muscle-preserving obesity drug, hands it back to Chugai

Roche has scrapped development of a muscle-building drug, ending a trial testing the experimental medicine in combination with an anti-obesity injectable. The Swiss pharma is stopping work on emugrobart, aptly named GYM329, and is returning ...